EA202190194A1 - Антитела к видам бактерий рода campylobacter - Google Patents

Антитела к видам бактерий рода campylobacter

Info

Publication number
EA202190194A1
EA202190194A1 EA202190194A EA202190194A EA202190194A1 EA 202190194 A1 EA202190194 A1 EA 202190194A1 EA 202190194 A EA202190194 A EA 202190194A EA 202190194 A EA202190194 A EA 202190194A EA 202190194 A1 EA202190194 A1 EA 202190194A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bacteria
antibodies
antibody
campylobacter
subject
Prior art date
Application number
EA202190194A
Other languages
English (en)
Russian (ru)
Inventor
Маттео Писсуто
Фабио Бениньи
Давиде Корти
Фабио Грасси
Лиса Перруцца
Original Assignee
Хьюмабс Байомед Са
Инститьют Фор Рисерч Ин Байомедисин
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хьюмабс Байомед Са, Инститьют Фор Рисерч Ин Байомедисин filed Critical Хьюмабс Байомед Са
Publication of EA202190194A1 publication Critical patent/EA202190194A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EA202190194A 2018-07-17 2019-07-16 Антитела к видам бактерий рода campylobacter EA202190194A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862699573P 2018-07-17 2018-07-17
PCT/US2019/042070 WO2020018584A2 (en) 2018-07-17 2019-07-16 Antibodies against campylobacter species

Publications (1)

Publication Number Publication Date
EA202190194A1 true EA202190194A1 (ru) 2021-04-16

Family

ID=67480448

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190194A EA202190194A1 (ru) 2018-07-17 2019-07-16 Антитела к видам бактерий рода campylobacter

Country Status (13)

Country Link
US (1) US12297258B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823727A2 (cg-RX-API-DMAC7.html)
JP (2) JP2021530237A (cg-RX-API-DMAC7.html)
KR (1) KR20210041557A (cg-RX-API-DMAC7.html)
CN (1) CN112867541B (cg-RX-API-DMAC7.html)
AU (1) AU2019306543A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000772A2 (cg-RX-API-DMAC7.html)
CA (1) CA3105222A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190194A1 (cg-RX-API-DMAC7.html)
IL (1) IL280234A (cg-RX-API-DMAC7.html)
MX (1) MX2021000268A (cg-RX-API-DMAC7.html)
SG (1) SG11202013193XA (cg-RX-API-DMAC7.html)
WO (1) WO2020018584A2 (cg-RX-API-DMAC7.html)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
WO2005028515A1 (ja) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. ヒトインスリン様成長因子に対する遺伝子組換え抗体
ES2358804T3 (es) * 2003-11-21 2011-05-13 Ace Biosciences A/S Polipéptidos de campylobacter jejuni ubicados en superficie.
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
MX2015005304A (es) 2012-10-24 2016-04-04 Nat Res Council Canada Anticuerpo contra campylobacter jejuni y usos para los mismos.
EP2995679A4 (en) 2013-03-11 2016-12-14 Kansai Bunri Sogo Gakuen PROCESS FOR PREPARING MONOCLONAL IGA ANTIBODIES

Also Published As

Publication number Publication date
MX2021000268A (es) 2021-06-08
EP3823727A2 (en) 2021-05-26
IL280234A (en) 2021-03-25
US12297258B2 (en) 2025-05-13
JP2024116266A (ja) 2024-08-27
KR20210041557A (ko) 2021-04-15
WO2020018584A2 (en) 2020-01-23
WO2020018584A3 (en) 2020-04-02
SG11202013193XA (en) 2021-02-25
US20210284718A1 (en) 2021-09-16
CA3105222A1 (en) 2020-01-23
CN112867541B (zh) 2024-08-30
AU2019306543A1 (en) 2021-01-28
CN112867541A (zh) 2021-05-28
BR112021000772A2 (pt) 2021-04-13
JP2021530237A (ja) 2021-11-11

Similar Documents

Publication Publication Date Title
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
MX2024006462A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
CR20200467A (es) Agentes anticuerpos anti-cd25
EA202091747A1 (ru) Составы антитела b7-h4
AU2017297757A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
MX2022008255A (es) Anticuerpo anti-il-13 para usarse en el tratamiento de esofagitis eosinofilica.
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
JOP20230311A1 (ar) أجسام مضادة لـ sirp-ألفا
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
EA202090559A1 (ru) Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение
EA202192810A1 (ru) АНТИТЕЛА К PcrV, КОТОРЫЕ СВЯЗЫВАЮТ PcrV, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К PcrV, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA202191666A1 (ru) Антитела к il-27 и их применение
BR112020015498A8 (pt) Anticorpos anti-pd-1
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA201990222A1 (ru) Антитела к o2 и пути их применения
BR112022026533A2 (pt) Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
BR112023020622A2 (pt) Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
MX2022014736A (es) Anticuerpos anti-cd200r1 y metodos de uso de estos.
EA202190647A1 (ru) Антитела к klrg1
BR112023023453A2 (pt) Anticorpo anti-tigit ou um fragmento de ligação ao antígeno deste e composições farmacêuticas compreendendo o referido anticorpo ou fragmento de ligação ao antígeno
BR112023026111A2 (pt) Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.